Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xbrane Biopharma AB ( (SE:XBRANE) ) just unveiled an announcement.
Xbrane Biopharma AB announced a teleconference for investors, analysts, and media to discuss its interim report for January to June 2025, scheduled for August 26, 2025. The report will be presented by CEO Martin Åmark and CFO Jane Benyamin, followed by a Q&A session. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology, which allows for significantly lower production costs compared to other systems. The company focuses on biosimilar candidates with a target market of EUR 23 billion in estimated annual peak sales. Xbrane’s lead candidate, Ximluci®, has received market authorization in Europe and was launched in 2023. The company is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 14,915,653
Technical Sentiment Signal: Sell
Current Market Cap: SEK437M
For a thorough assessment of XBRANE stock, go to TipRanks’ Stock Analysis page.